DEBIRI plus chemo vs. chemo alone for liver metastases
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if a treatment called DEBIRI (tiny beads delivering chemo directly to the liver) plus standard chemotherapy works better than chemotherapy alone for colorectal cancer that has spread to the liver and can't be fully removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer has spread to the liver, and doctors cannot remove all the liver tumors with surgery (or it's uncertain).
- You have not had chemotherapy for the cancer that spread to the liver.
- You are in generally good health (able to do daily activities).
- Your liver, kidneys, and blood counts are within acceptable ranges (will be checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to treat colorectal cancer that has spread to the liver and cannot be removed by surgery. It tests if combining a targeted chemo bead procedure (DEB-TACE) with liver chemo infusion (HAIC) works better than HAIC alone.
This trial tests whether using chemotherapy beads delivered directly to the liver (DEB-TACE) before a living donor liver transplant improves outcomes for people with liver cancer. If you have a tumor in the right side of the liver that fits certain size and number limits, and you are already scheduled for a transplant, this study may be an option.
This trial tests a combination of four treatments for people with bile duct cancer that cannot be removed by surgery. The treatments include chemotherapy directly into the liver, tiny beads with chemo, an immunotherapy drug, and a targeted therapy pill. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of treatments for people with liver cancer that can be surgically removed. The goal is to see if the combination helps shrink tumors and improve outcomes before surgery.
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
This trial tests whether a combination of two treatments—chemoembolization (DEB-TACE) plus chemotherapy given through the liver artery (RALOX-HAIC)—works better than chemoembolization alone for people with large liver cancer tumors (over 7 cm). The goal is to see if the combination shrinks tumors more effectively.
Hear when a new Liver Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.